Onartuzumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | scatter factor receptor kinase |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C4422H6820N1168O1363S31 |
| Molar mass | 99147.88 g·mol−1 |
  (what is this?) (verify) | |
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.[1][2][3]
Onartuzumab was developed by Genentech, Inc. It is undergoing clinical trials.[4][5][6][7]
References
[edit]- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
- ^ Padda S, Neal JW, Wakelee HA (December 2012). "MET inhibitors in combination with other therapies in non-small cell lung cancer". Transl Lung Cancer Res. 1 (4): 238–53. doi:10.3978/j.issn.2218-6751.2012.10.08. PMC 4367550. PMID 25806189.
- ^ Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F (May 2015). "Onartuzumab in lung cancer: the fall of Icarus?". Expert Rev Anticancer Ther. 15 (5): 487–9. doi:10.1586/14737140.2015.1031219. PMID 25818471.
- ^ Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S (November 2013). "Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors". J Clin Pharmacol. 53 (11): 1103–11. doi:10.1002/jcph.148. PMID 23922054. S2CID 206059437.
- ^ Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H (November 2012). "Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer". Clin Lung Cancer. 13 (6): 500–4. doi:10.1016/j.cllc.2012.05.009. PMID 23063071.
- ^ Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC (November 2013). "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer". J. Clin. Oncol. 31 (32): 4105–14. doi:10.1200/JCO.2012.47.4189. PMC 4878106. PMID 24101053.
- ^ Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T (June 2015). "Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer". Invest New Drugs. 33 (3): 632–40. doi:10.1007/s10637-015-0227-5. PMID 25777467. S2CID 20118425.
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF | |||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
